GlassScriptPhysician profile
Edward J Choi
NPI 1255362604
$12,835.76
in general payments reported to CMS, 2019-2025
42 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,575 · 2020: $1,018 · 2021: $2,581 · 2022: $1,782 · 2023: $1,704 · 2024: $1,447 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,859 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,859.38 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,968.91 | 2019-2025 | Mitraclip, Cardiomems, Aveir |
| Amgen INC. | $1,057.13 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,055.31 | 2019-2025 | |
| Boston Scientific Corporation | $765.77 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $732.11 | 2019-2025 | Eliquis, Camzyos |
| Novo Nordisk INC | $669.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $601.24 | 2021-2025 | Symplicity G3, Endurant Iis, Onyx Frontier |
| Pfizer INC. | $566.79 | 2019-2025 | |
| Abiomed | $548.74 | 2019-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $527.41 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $475.65 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $299.98 | 2019-2024 | |
| Amarin Pharma, INC. | $274.96 | 2019-2023 | |
| Cvrx, INC. | $246.50 | 2021-2025 | Barostim Neo System |
| Bridgebio Pharma, INC. | $209.25 | 2025 | Attruby |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.